Dermira Inc (DERM):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Dermira Inc (DERM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8230
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:56
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Dermira Inc (Dermira) is a biopharmaceutical company that identifies, develops and commercializes therapeutic solutions for the treatment of dermatologic diseases, such as hyperhidrosis, acne vulgaris and atopic dermatitis. The company’s product includes QBREXZA (glycopyrronium) cloth, an anticholinergic indicated for the treatment of primary axillary hyperhidrosis in pediatric and adult patients. Its pipeline products include Lebrikizumab, an injectable humanized monoclonal antibody intended for the treatment of moderate-to-severe atopic dermatitis; and other early-stage research programs in other areas of dermatology. Dermira is headquartered in Menlo Park, California, the US.

Dermira Inc (DERM) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Dermira Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Dermira Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Dermira Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Dermira Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Dermira Inc, Medical Devices Deals, 2012 to YTD 2018 10
Dermira Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Dermira Inc, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Dermira Raises USD0.5 Million in Venture Financing 13
Dermira Raises USD1.5 Million in Venture Financing 14
Dermira Raises USD51 Million In Series C Venture Financing 15
Dermira Raises US$35 Million In Series B Financing 17
Dermira Raises USD25 Million in Venture Financing 19
Dermira Raises US$34 Million In Venture Financing 20
Partnerships 21
ImaBiotech Enters into Agreement with Dermira 21
Licensing Agreements 22
Dermira Enters into Licensing Agreement with F. Hoffmann-La Roche and Genentech for Lebrikizumab 22
Maruho Enters into Licensing Agreement with Dermira for DRM04 24
Dermira Enters into Option Agreement with Takeda Pharma 25
Dermira Enters Into Licensing Agreement with Rose U 26
Equity Offering 27
Dermira Raises USD193.8 Million in Public Offering of Shares 27
Dermira Raises USD145 Million in Public Offering of Shares 29
Dermira Raises USD111.3 Million in Public Offering of Shares 31
Dermira Raises USD125 Million in IPO of Shares 33
Dermira Raises USD7.5 Million in Private Placement of Shares 35
Debt Offering 37
Dermira Raises USD287.5 Million in Private Placement of 3% Notes Due 2022 37
Dermira Inc – Key Competitors 38
Dermira Inc – Key Employees 39
Dermira Inc – Locations And Subsidiaries 40
Head Office 40
Recent Developments 41
Financial Announcements 41
Aug 06, 2018: Dermira reports second quarter 2018 financial results and provides corporate update 41
May 03, 2018: Dermira Reports First Quarter 2018 Financial Results and Provides Corporate Update 43
Feb 22, 2018: Dermira Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update 45
Nov 06, 2017: Dermira Reports Third Quarter 2017 Financial Results 47
Aug 07, 2017: Dermira Reports Second Quarter 2017 Financial Results and Provides Corporate Update 48
May 08, 2017: Dermira Reports First Quarter 2017 Financial Results and Provides Corporate Update 49
Feb 28, 2017: Dermira Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update 51
Corporate Communications 53
Jan 04, 2017: Dermira Elects Emmanuel Caeymaex to Board of Directors 53
Other Significant Developments 54
Jan 06, 2017: Dermira Provides Corporate Update 54
Appendix 56
Methodology 56
About GlobalData 56
Contact Us 56
Disclaimer 56

List of Tables
Dermira Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Dermira Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Dermira Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Dermira Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Dermira Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Dermira Inc, Medical Devices Deals, 2012 to YTD 2018 10
Dermira Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Dermira Raises USD0.5 Million in Venture Financing 13
Dermira Raises USD1.5 Million in Venture Financing 14
Dermira Raises USD51 Million In Series C Venture Financing 15
Dermira Raises US$35 Million In Series B Financing 17
Dermira Raises USD25 Million in Venture Financing 19
Dermira Raises US$34 Million In Venture Financing 20
ImaBiotech Enters into Agreement with Dermira 21
Dermira Enters into Licensing Agreement with F. Hoffmann-La Roche and Genentech for Lebrikizumab 22
Maruho Enters into Licensing Agreement with Dermira for DRM04 24
Dermira Enters into Option Agreement with Takeda Pharma 25
Dermira Enters Into Licensing Agreement with Rose U 26
Dermira Raises USD193.8 Million in Public Offering of Shares 27
Dermira Raises USD145 Million in Public Offering of Shares 29
Dermira Raises USD111.3 Million in Public Offering of Shares 31
Dermira Raises USD125 Million in IPO of Shares 33
Dermira Raises USD7.5 Million in Private Placement of Shares 35
Dermira Raises USD287.5 Million in Private Placement of 3% Notes Due 2022 37
Dermira Inc, Key Competitors 38
Dermira Inc, Key Employees 39

List of Figures
Dermira Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Dermira Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Dermira Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Dermira Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Dermira Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Dermira Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Dermira Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Dermira Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Dermira Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Dermira Inc (DERM):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Vionx Energy Corp:電力:M&Aディール及び事業提携情報
    Summary Vionx Energy Corp (Vionx Energy), formerly Premium Power Corp, is a diversified company. The company provides traditional vanadium redox flow batteries and patented battery stack that employs various components including tanks of anolyte and catholyte fluids, power cell at the center of the …
  • Woori Bank:企業の戦略・SWOT・財務情報
    Woori Bank - Strategy, SWOT and Corporate Finance Report Summary Woori Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • BlueScope Steel Ltd:企業のM&A・事業提携・投資動向
    BlueScope Steel Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's BlueScope Steel Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), …
  • Investec Private Bank (UK & Europe):企業の戦略・SWOT・財務情報
    Investec Private Bank (UK & Europe) - Strategy, SWOT and Corporate Finance Report Summary Investec Private Bank (UK & Europe) - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Alchemia Ltd (ACL)-製薬・医療分野:企業M&A・提携分析
    Summary Alchemia Ltd (Alchemia) is a biopharmaceutical company that focuses on the discovery and development of drugs for the treatment of cancer and respiratory disorders. It sold the worldwide exclusive intellectual property rights to its product, Fondaparinux sodium (a generic version of the anti …
  • Atara Biotherapeutics Inc (ATRA):企業の財務・戦略的SWOT分析
    Atara Biotherapeutics Inc (ATRA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Lenzing AG (LNZ):企業の財務・戦略的SWOT分析
    Lenzing AG (LNZ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Sierra Nevada Corporation:企業の戦略・SWOT・財務情報
    Sierra Nevada Corporation - Strategy, SWOT and Corporate Finance Report Summary Sierra Nevada Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Suncorp Group Ltd:企業のM&A・事業提携・投資動向
    Suncorp Group Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Suncorp Group Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), div …
  • Laboratoires Thea SA-製薬・医療分野:企業M&A・提携分析
    Summary Laboratoires Thea SA (Thea) is an independent pharmaceutical company that researches, develops, manufactures, and commercializes a range of eye care products. The company’s products find application in the diagnosis, surgery and treatment of ophthalmic diseases such as dry eye, allergies, gl …
  • Black Box Corp:企業の戦略的SWOT分析
    Black Box Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • VidaCaixa, S.A.U. de Seguros y Reaseguros:企業の戦略・SWOT・財務情報
    VidaCaixa, S.A.U. de Seguros y Reaseguros - Strategy, SWOT and Corporate Finance Report Summary VidaCaixa, S.A.U. de Seguros y Reaseguros - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SW …
  • Vertex Pharmaceuticals Inc (VRTX):企業の財務・戦略的SWOT分析
    Vertex Pharmaceuticals Inc (VRTX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • The Boeing Co (BA):企業の財務・戦略的SWOT分析
    The Boeing Co (BA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Silver Bull Resources, Inc.:企業の戦略・SWOT・財務情報
    Silver Bull Resources, Inc. - Strategy, SWOT and Corporate Finance Report Summary Silver Bull Resources, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Bank of Nanjing Co., Ltd.:戦略・SWOT・企業財務分析
    Bank of Nanjing Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Bank of Nanjing Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Heineken UK Ltd:企業の戦略・SWOT・財務情報
    Heineken UK Ltd - Strategy, SWOT and Corporate Finance Report Summary Heineken UK Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Canon Medical Systems Corp:企業の製品パイプライン分析
    Summary Canon Medical Systems Corp (Canon Medical Systems), is a provider of medical diagnostic systems. The company’s major products include computed tomography systems, magnetic resonance imaging systems, ultrasound systems, X-ray; magnetic resonance systems; advanced visualization and nuclear med …
  • Pakistan Refinery Ltd (PRL):石油・ガス:M&Aディール及び事業提携情報
    Summary Pakistan Refinery Ltd (PRL) is a downstream oil and gas company. It carries out refining, production and supply of refined petroleum products. It operates a hydro skimming refinery, which is designed to process various imported and local crude oil into distilled petroleum products such as fu …
  • Red Sky Energy Ltd (ROG):石油・ガス:M&Aディール及び事業提携情報
    Summary Red Sky Energy Ltd (Red Sky Energy) is an oil and gas exploration company that explores, develops, and produces oil and coal steam gas. The company’s gas projects comprise Taroom Trough Project and Clarence Moreton project. Its Clarence Moreton project operates a gas reserve position in Wall …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆